Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

byBenzinga Newsdesk

November 29, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

Susquehanna Downgrades Enphase Energy to Neutral, Announces $365 Price Target

By Benzinga Newsdesk

December 15, 8:29 AM

Susquehanna analyst Biju Perincheril downgrades Enphase Energy (NASDAQ:ENPH) from Positive to Neutral and announces $365 price target.

ENPH

Eastman Chemical (EMN) To Post Q2 Earnings: Factors At Play

By Zacks

July 26, 3:05 PM

Eastman Chemical Company (NYSE: EMN) is set to release second-quarter 2022 results after the closing bell on Jul 28.

ALB

Analyst Ratings

What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals

By Benzinga Insights

January 3, 2:00 PM

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

APLS

News

Overview Of Value Stocks In The Consumer Defensive Sector

By Benzinga Insights

March 31, 10:40 AM

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices…

Oppenheimer Downgrades CinCor Pharma to Perform

Related Posts

Susquehanna Downgrades Enphase Energy to Neutral, Announces $365 Price Target

Eastman Chemical (EMN) To Post Q2 Earnings: Factors At Play

What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals

Overview Of Value Stocks In The Consumer Defensive Sector